Moderna

Moderna's application for its mRNA-based flu shot was refused by the United States===Food and Drug Administration, causing its shares to drop 8%. This decision is a significant setback for Moderna's vaccine development efforts and its expansion into the flu vaccine market.

Moderna settled a legal battle over its COVID-19 vaccine technology, agreeing to pay up to $2.25 billion. This settlement removes a significant legal overhang, allowing Moderna to focus on its cancer vaccine pipeline and improving investor confidence. The company's stock rose 9% following the announcement.

Moderna has agreed to pay up to $2.25 billion to settle a patent dispute with Roivant Sciences===Genevant Sciences and Arbutus Biopharma, resolving all U.S. and international legal actions. This settlement removes the risk of future royalty payments for its LNP technology in upcoming vaccines and is seen as positive given its past vaccine sales.

Moderna entered into a collaboration and license agreement with Recordati to develop and commercialize mRNA-3927. Moderna will receive an upfront payment of $50 million and up to an additional $110 million in near-term development and regulatory milestones, plus commercial milestones and tiered royalties on net sales. This deal strengthens Moderna's position in rare disease therapeutics.

Moderna has agreed to a $2.25 billion settlement with Roivant Sciences===Genevant Sciences and Arbutus Biopharma Corporation for unauthorized use of LNP delivery technology in its COVID-19 vaccines. This settlement includes an upfront payment of $950 million and a contingent payment of $1.3 billion. Moderna will also receive a global non-exclusive license to Roivant Sciences===Genevant Sciences' LNP delivery technology for infectious disease applications.